Investing.com --Jiangsu Hengrui Pharmaceuticals (HK:1276) shares rose in Hong Kong on Tuesday after Novo Nordisk entered an agreement to license the Chinese drugmaker's experimental obesity and diabetes treatment in a deal worth up to $2.6 billion. Still guessing which names to buy? Our AI rebuilds its stock picks at the start of every month. The list is beating the market by 120%. See what's on it » Hengrui shares were up 1.5% at HK$45.44, sharply outperforming the Hang Seng Index, which was down 1%. Under the agreement, Novo will gain exclusive rights to develop, manufacture and commercialize HRS-1596 globally, excluding mainland China, Hong Kong, Macao and Taiwan. Should you buy NVIDIA right now?
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.